Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JPMY | ISIN: US64131A1051 | Ticker-Symbol: NRC
München
16.04.24
08:04 Uhr
3,980 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURONETICS INC Chart 1 Jahr
5-Tage-Chart
NEURONETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6204,02022:30

Aktuelle News zur NEURONETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNeuronetics: New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital2
01.04.Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression1
27.03.Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)45MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
26.03.Neuronetics' magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression1
25.03.Neuronetics, Inc. - 8-K, Current Report-
25.03.FDA clears Neuronetics' neurostim for adolescents with depression1
25.03.Neuronetics gets FDA nod for NeuroStar as add-on treatment for adolescents with depression1
25.03.Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication-
25.03.Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression408MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
► Artikel lesen
08.03.Neuronetics (STIM) Progresses in MRD and TRD With New Deal1
08.03.Neuronetics, Inc. - 10-K, Annual Report-
07.03.Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript1
07.03.Neuronetics to supply TMS equipment to Transformations Care Network1
07.03.Neuronetics announces 5-year exclusive partnership with TCN1
06.03.Earnings call: Neuronetics shows growth and positive cash flow outlook1
06.03.Neuronetics Inc reports results for the quarter ended in December - Earnings Summary1
05.03.Medtech co Neuronetics rises on upbeat Q4 results1
05.03.Neuronetics GAAP EPS of -$0.19 beats by $0.07, revenue of $20.31M beats by $0.31M1
05.03.Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results78MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming...
► Artikel lesen
05.03.Neuronetics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1